

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO
ALLIA.143C1APPLICATION NO
09/623,728INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Habib ZaghouaniFILING DATE
January 22, 2001

GROUP

~~1616~~ 1614

FEB 12 2002

1,600/2900

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
11	1	5,474,771	12/12/95	Lederman, et al.			
	2	5,508,386	04/16/96	Zanetti, et al.			
	3	5,612,035	03/18/97	Howell, et al.			
	4	5,969,109	10/19/99	Bona, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
IN	5	EP 0 629 703	12/21/94	Europe				
	6	WO 90/02017	03/08/90	PCT				
	7	WO 92/05793	04/16/92	PCT				
	8	WO 93/06135	04/01/93	PCT				
	9	WO 93/10220	05/11/94	PCT				
	10	WO 94/10332	05/11/94	PCT				
	11	WO 94/14847	07/07/94	PCT				
	12	WO 94/28027	12/08/94	PCT				
	13	WO 95/23814	09/08/95	PCT				
	14	WO 96/16086	05/30/96	PCT				
	15	WO 96/19534	06/27/96	PCT				
	16	WO 96/34622	11/07/96	PCT				
	17	WO 98/30706	07/16/98	PCT				
	18	WO 99/09064	02/25/99	PCT				
	19	WO 00/01732	01/13/00	PCT				

EXAMINER

Patricia J. Nelson

DATE CONSIDERED

2/24/02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO ALLIA.143C1	APPLICATION NO 09/623,728
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Habib Zaghouani	
		FILING DATE January 22, 2001	GROUP 1616 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
20	Adorini, et al., New Perspectives on Immunointervention in Autoimmune Diseases, Immunol. Today, 11(11):383-386 (1990)	
21	Arnold et al., Multiple Levels of Peripheral Tolerance, Immunol. Today, 14: 12-14 (1993)	
22	Ashton-Rickardt, et al., Evidence for a Differential Avidity Model of T Cell Selection in the Thymus, Cell 76: 651-663 (1994)	
23	Asseman et al., An Essential Role for Interleukin 10 in the Function of Regulatory T Cells That Inhibit Intestinal Inflammation, J. Exp. Med., 190: 995-1003 (1999)	
24	Berger, et al., Immune Complex-Induced Interleukin-6, Interleukin-10 and Prostaglandin Secretion by Human Monocytes: a Network of Pro- and Anti-Inflammatory Cytokines Dependent on the Antigen: Antibody Ratio, Eur. J. Immunol., 26: 1297-1301 (1996)	
25	Berger, et al., Immune Complexes are Potent Inhibitors of Interleukin-12 Secretion by Human Monocytes, Eur. J. Immunol., 27: 2994-3000 (1997)	
26	Bona, et al., Immunogenicity of Microbial Peptides Grafted in Self Immunoglobulin Molecules, Cellular and Molecular Biology, Vol. 40 Suppl. I, 21-30 (1994)	
27	Brocke, et al., Treatment of Experimental Encephalomyelitis with a Peptide Analogue of Myelin Basic Protein, Nature 379: 343-346 (25 January 1996)	
28	Chen et al., Oral Tolerance in Myelin Basic Protein T-Cell Receptor Transgenic Mice: Suppression of Autoimmune Encephalomyelitis and Dose-Dependent Induction of Regulatory Cells, Proc. Natl. Acad. Sci. USA, 93: 388-391 (1996)	
29	Chou, et al., Frequency of T Cells Specific for Myelin Basic Protein and Myelin Proteolipid Protein in Blood and Cerebrospinal Fluid in Multiple Sclerosis, J. of Neuroimmunology 38: 105-114 (1992)	
30	Christian, Studies of Aggregated γ -Globulin, J. Immunol., 84:112-121 (1960)	
31	Cibotti, et al., Tolerance to a Self-Protein Involves Its Immunodominant But Does Not Involve Its Subdominant Determinants, Proc. Natl. Acad. Sci. USA 9:416-420 (1992)	
32	Cullen, et al., A Divalent Major Histocompatibility Complex/IgG1 Fusion Protein Induces Antigen-specific T Cell Activation <i>in vitro</i> and <i>in vivo</i> , Cellular Immunology 192(1):54-62 (1999).	
33	De Magistris, et al., Antigen Analog-Major Histocompatibility Complexes Act as Antagonists of the T Cell Receptor, Cell 68: 625-634 (1992)	
34	Ding et al., IL-10 Inhibits Macrophage Costimulatory Activity by Selectively Inhibiting the Up-Regulation of B7 Expression, J. Immunol., 151: 1224-1234 (1993)	
35	Endoh, et al., Studies of Experimental Allergic Encephalomyelitis in Old Mice, J. of Neuroimmunol., 29:21-31 (1990)	
36	Evavold, et al., Tickling the TCR: Selective T-Cell Functions Stimulated by Altered Peptide Ligands, Immunology Today 14(12): 620-609 (1993)	
37	Evavold, et al., Separation of IL-4 Production From Th Cell Proliferation by an Altered T Cell Receptor Ligand, Science 252: 1308-1310 (1991)	
38	Falcone, et al., A T Helper Cell 2 (Th2) Immune Response against Non-self Antigens Modifies the Cytokine Profile of Autoimmune T Cells and Protects against Experimental Allergic Encephalomyelitis, J. Exp. Med., 185: 901-901 (1997)	
39	Feldman, et al., Rheumatoid Arthritis, Cell 85: 307-310 (3 May 1996)	
40	Fiorentino et al., IL-10 Acts on the Antigen-Presenting Cell to Inhibit Cytokine Production by Th1 Cells, J. Immunol., 146: 3444-51 (1991)	
41	Fowlkes et al., T-Cell Tolerance, Curr. Opin. Immunol., 5: 873-879 (1993)	
42	Gosselin, et al., Enhanced Antigen Presentation Using Human Fc γ Receptor (Monocyte/Macrophage)-Specific Immunogens, J. Immunol., 149(11):3477-3481 (1992)	
43	Groux et al., Regulatory T Cells and Inflammatory Bowel Disease, Immunol. Today, 20: 442-445 (1999)	
44	Groux, et al., A CD4+ T-Cell Subset Inhibits Antigen-Specific T-Cell Responses and Prevents Colitis, Nature (Lond.), 389: 737-742 (1997)	
45	Hsu, et al., Modulation of T Cell Development by an Endogenous Altered Peptide Ligand, J. Exp. Med. 181: 805-810 (1995)	
46	Hurtenbach, et al., J. Exp. Medicine Vol. 177: 1499-1504 (1993)	
47	Jameson, et al., Clone-Specific T Cell Receptor Antagonists of Major Histocompatibility Complex Class I-Restricted Cytotoxic T. Cells, J. Exp. Med. 177: 1541-1550 (1993)	
48	Jameson, et al., Positive Selection of Thymocytes, Annu. Rev. Immunol. 13: 93-126 (1995)	

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO ALLIA.143C1	APPLICATION NO 09/623,728
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Habib Zaghouani	
		FILING DATE January 22, 2001	GROUP 1645 1644

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
49	Jenkins et al., Molecules Involved in T-Cell Costimulation, Curr Opin. Immunol., 5: 361-367 (1993)	
50	Karin, et al., Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myeline Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon γ and Tumor Necrosis Factor α Production, J. Exp. Med. 180 2227-2237 (1994)	
51	Karpus, et al., Inhibition of Relapsing Experimental Autoimmune Encephalomyelitis in SJL Mice by Feeding the Immunodominant PLP 139-151 Peptide, J. Neurosci. Res. 45: 410-423 (1996)	
52	Klassen, et al., Blood Flow and Tissue Space of the Left Coronary Artery in Man, Circulation Res. 27: 185-195 (1970)	
53	Kosaka et al., Tolerance of CD8+ T Cells Developing in Paretrn F1 Chimeras Prepared with Supralethal Irradiation: Step-Wise Induction of Tolerance in the Intrathymic and Extrathymic Environments, J. Exp. Med., 177: 367-378 (1993)	
54	Kuchroo, et al., Experimental Allergic Encephalomyelitis Mediated by Clone T Cells Specific for a Synthetic Peptide of Myelin Proteolipid Protein, J. of Immunology 148(12): 3776-3782 (1992)	
55	Kuchroo, et al., A Single TCR Antagonist Peptide Inhibits Experimental Allergic Encephalomyelitis Mediated by a Diverse T Cell Repertoire, J. of Immunology 153: 3326-3336 (1994)	
56	Legge, et al., (1997) Presentation of a T-cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or protein requiring endocytic processing, J. Exp. Med. 185(6): 1043-1053	
57	Liu, et al., Low Avidity Recognition of Self-Antigen by T Cells Permits Escape from Central Tolerance, Immunity 3: 407-415 (1995)	
58	Liu, C. et al., (1996) Fc γ RI-Targeted Fusion Proteins Result in Efficient Presentation by Human Monocytes of Antigenic and Antagonist T Cell Epitopes, J. Clin. Invest. 98(9): 2001-2007	
59	Liu, et al., Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice-implications for autoimmunity, Int. Imm. 7(8): 1255-1263 (1995)	
60	Livingstone, et al., Ann. Rev. Immuno. Vol 5: 477-501 (1987)	
61	Ma, et al., Inhibition of Collagen-Induced Arthritis in Mice by Viral IL-10 Gene Transfer, J. Immunol., 161: 1516-1524 (1998)	
62	Mamula, Mark J., The Inability to Process a Self-Peptide Allows Autoreactive T Cells to Escape Tolerance, J. Exp. Med. 177: 567-571 (1993)	
63	Martin, et al., Immunological Aspects of Demyelinating Diseases, Annu. Rev. Immunol. 10: 153-187 (1992)	
64	Mathisen et al., Treatment of Experimental Autoimmune Encephalomyelitis with Genetically Modified Memory T Cells, J. Exp. Med. 186: 159-164 (1997)	
65	McCormack et al., Profound Deletion of Mature T Cells in Vivo by Chronic Exposure to Exogenous Superantigen, J. Immunol., 150: 3785-3792 (1993)	
66	McRae, et al., Functional Evidence for Epitope Spreading on the Relapsing Pathology of Experimental Autoimmune Encephalomyelitis, J. Exp. Med. 182: 75-85 (1995)	
67	Min, et al., Modulation in Vivo of Autoreactive T Cells by a TCR Antagonist Ig Chimera, J. of Allergy & Clinical Immunology 99(1): 738 (January 1997)	
68	Min, B. et al., (1998) Neonatal Exposure to a Self-Peptide-Immunoglobulin Chimera Circumvents the Use of Adjuvant and Confers Resistance to Autoimmune Disease by a Novel Mechanism Involving Interleukin 4 Lymph Node Deviation and Interferon γ -mediated Splenic Anergy, J. Exp. Med. 188(11): 2007-2017	
69	Moore et al., Interleukin-10 and the Interleukin-10 Receptor, Annu. Rev. Immunol., 19: 683-765 (2001)	
70	Muller, et al., Selective <i>in vivo</i> Inhibition of T Cell Activation by Class II MHC-Binding Peptides Administered in Soluble Form, J. Immunol., 145(12):4006-4011 (1990)	
71	Panka, et al., Proc. Natl. Acad. Sci. USA Vol. 85: 3080-3084 (1988)	
72	Peguet-Navarro et al., Interleukin-10 Inhibits the Primary Allogeneic T Cell Response to Human Epidermal Langerhans Cells, J. Immunol., 24: 884-891 (1994)	
73	Riechmann, et al., Reshaping human antibodies for therapy, Nature, Vol. 332, March 24: 323-327 (1988)	
74	Rocha et al., Peripheral Selection of the T Cell Repertoire, Science (Washington, D.C.), 251: 1225-1228 (1991)	
75	Rosenqvist et al., Thermal Properties of Humg IgG, Mol. Immunol., 24: 495-501 (1987)	
76	Rudikoff, et al., Proc. Natl. Acad. Sci. USA Vol. 179: 1979-1983 (1982)	
77	Sebzda, et al., Positive and Negative Thymocyte Selection Induced by Different Concentrations of a Single Peptide, Science 263: 1615-1618 (1994)	

EXAMINER	DATE CONSIDERED
EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ALLIA.143C1	APPLICATION NO 09/623,728
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Habib Zaghouani	
		FILING DATE January 22, 2001	GROUP 1015 / 1.4/2

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
FN	78	Seddon et al., Peripheral Autoantigen Induces Regulatory T Cells that Prevent Autoimmunity, J. Exp. Med., 189: 877-881 (1999)
	79	Seddon et al., The Third Function of the Thymus, Immunol. Today, 21: 95-99 (2000)
	80	Sercarz, et al., Dominance and Crypticity of T Cell Antigenic Determinants, Annu. Rev. Immunol. 11: 729-766 (1993)
	81	Shaw, et al., Local Delivery of Interleukin 4 by Retrovirus-Transduced T Lymphocytes Ameliorates Experimental Autoimmune Encephalomyelitis, J. Exp. Med., 185: 1711-1714 (1997)
	82	Sollazzo, et al., Expression of an exogenous peptide epitope genetically engineered in the variable domain of an immunoglobulin: implications for antibody and peptide folding, Protein Engineering, Vol. 4, No. 2: 215-220 (1990)
	83	Steinbrink et al., Induction of Tolerance by IL-10-Treated Dendritic Cells, J. Immunol., 159: 4772-4780 (1997)
	84	Steinman, Lawrence Multiple Sclerosis: A Coordinated Immunological Attack Against Myelin in the Central Nervous System, Cell 85: 299-302 (3 May 1996)
	85	Stohman, et al., Activation of Regulatory Cells Suppresses Experimental Allergic Encephalomyelitis Via Secretion of IL-10, 163: 6338-6344 (1999)
	86	Sutterwala, et al., Reversal of Proinflammatory Responses by Ligating the Macrophage Fcγ Receptor Type I, J. Exp. Med., 188: 217-222 (1998)
	87	Takemori, et al., Mechanism of Neonatally Induced Idiotype Suppression and its Relevance for the Acquisition of Self-tolerance, Immunological Reviews, 79: 103-117
	88	Tisch, et al., Insulin-Dependent Diabetes Mellitus, Cell 85: 291-297 (3 May 1996)
	89	Tuohy, et al., Identification of an Encephalitogenic Determinant of Myelin Proteolipid Protein for SJL Mice, J. of Immunology 142(5): 1523-1527 (1989)
	90	Tuohy et al., The Epitope Spreading Cascade During Progression of Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis, Immunol. Rev., 164: 93-100 (1998)
	91	Webb et al., Extrathymic Tolerance of Mature T Cells: Clonal Elimination as a Consequence of Immunity, Cell., 63: 1249-1256 (1990)
	92	Williams et al., Chemical Analyses, Methods in Immunology and Immunochemistry, Academic Press, New York and London, 2: 249-341 (1968)
	93	Willems et al., Interleukin-10 Inhibits B7 and Intercellular Adhesion Molecule-1 Expression on Human Monocytes, Eur. J. Immunol., 24: 1007-1009 (1994)
	94	Windhagen, et al., Modulation of Cytokine Patterns of Human Autoreactive T Cell Clones by a Single Amino Acid Substitution of Their Peptide Ligand, Immunity 2: 373-380 (1995)
	95	Wucherpfennig, et al., Molecular Mimicry in T Cell-Mediated Autoimmunity: Viral Peptides Activate Human T Cell Clones Specific for Myeline Basic Protein, Cell 80: 695-705 (1995)
	96	Zaghouani et al., Cells Expressing an H Chain Ig Gene Carrying a Viral T Cell Epitope are Lysed by Specific Cytolytic T Cells, J. Immunol., 148: 3604-3609 (1992)
	97	Zaghouani et al., Presentation of a Viral T Cell Epitope Expressed in the CDR3 Region of a Self Immunoglobulin Molecule, Science, 259: 224-227 (1993)
	98	Zaghouani, et al., Induction of Antibodies to the Envelope Protein of the Human Immunodeficiency Virus by Immunization with Monoclonal Anti-Idiotypes, Proc. Natl. Acad. Sci USA, 88: 5645-5649, (1991)
	99	Zaghouani, et al., Engineered Immunoglobulin Molecules as Vehicles for T Cell Epitopes, Intern. Rev. Immunol., 10: 265-278 (1993)
	100	Zaghouani, Habib, U.S. App. No. 08/779,767, filed 01/07/97, entitled "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143A
	101	Zaghouani, Habib, 08/779,767, filed 01/07/97, Currently Pending Claims - "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143A
	102	Zaghouani, Habib, 09/341,011 (U.S. Natl. Phase of PCT App. No. PCT/US98/00520), filed 10/12/99, Currently Pending Claims - "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143APC
	103	Zaghouani, Habib, U.S. App. No. 09/111,123, filed 07/06/98, entitled "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143CP2
	104	Zaghouani, Habib, 09/111,123, filed 07/06/98, Currently Pending Claims - "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA.143CP2
✓	105	Zaghouani, Habib, U.S. App. No. 09/873,901, filed 06/04/01, entitled "Coupling of Peripheral Tolerance to Endogenous IL-10 Promotes Effective Modulation of T Cells and Ameliorates Autoimmune Disease," Docket No. ALLIA.143CP3

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ALLIA 143C1	APPLICATION NO 09/623,728
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Habib Zaghouani	
		FILING DATE January 22, 2001	GROUP 1615

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
106	Zaghouani, Habib, 09/873,901, filed 06/04/01, Currently Pending Claims - "Coupling of Peripheral Tolerance to Endogenous IL-10 Promotes Effective Modulation of T Cells and Ameliorates Autoimmune Disease," Docket No. ALLIA 143CP3	
107	Zaghouani, Habib, U.S. App. No. 10/000,868, filed 11/30/01, entitled "Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors," Docket No. ALLIA 143DV1	
108	Zhang, et al., Increased Frequency of Interleukin 2-Responsive T Cells Specific for Myeline Basic Protein and Proteolipid Protein in Peripheral Blood and Cerebrospinal Fluid of Patients with Multiple Sclerosis, J. Exp. Med. 179: 973-984 (1994)	
109	International Search Report for co-pending Application No. PCT/US01/40834	

S:\DOCS\SGJ\SGJ-1299.DOC
101901

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	